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Evaluation of Adeno-Associated Viral Vectors for Liver-Directed Gene
Transfer in Dogs
Abstract
This study evaluated six adeno-associated viral (AAV) vectors expressing green fluorescent protein (GFP)
from the liver-specific thyroid hormone–binding globulin (TBG) promoter made with novel capsids in
canine liver-directed gene transfer. Studies in 1.5-month-old dogs, which were administered vector through a
peripheral vein, showed that AAV8 capsid vectors had the most favorable performance profiles. Interestingly,
the absolute levels of hepatocyte transduction achieved with AAV8 were lower in dogs compared with what
had been achieved in mice and nonhuman primates. Additional studies were performed with AAV8 delivered
into the hepatic artery in adult dogs, with higher doses of vector used to assess potential dose-limiting
toxicities. These studies showed good transduction on day 7 in one dog that apparently was lost by day 28 in
another dog through the generation of GFP-specific T cells. Each adult dog was carefully monitored for any
hemodynamic changes associated with vector infusion. Both animals demonstrated mild to moderate
hypotension and bradycardia, which appeared to be anesthesia-related, making it difficult to evaluate
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Abstract
This study evaluated six adeno-associated viral (AAV) vectors expressing green fluorescent protein (GFP) from
the liver-specific thyroid hormone–binding globulin (TBG) promoter made with novel capsids in canine liver-
directed gene transfer. Studies in 1.5-month-old dogs, which were administered vector through a peripheral
vein, showed that AAV8 capsid vectors had the most favorable performance profiles. Interestingly, the absolute
levels of hepatocyte transduction achieved with AAV8 were lower in dogs compared with what had been
achieved in mice and nonhuman primates. Additional studies were performed with AAV8 delivered into the
hepatic artery in adult dogs, with higher doses of vector used to assess potential dose-limiting toxicities. These
studies showed good transduction on day 7 in one dog that apparently was lost by day 28 in another dog
through the generation of GFP-specific T cells. Each adult dog was carefully monitored for any hemodynamic
changes associated with vector infusion. Both animals demonstrated mild to moderate hypotension and bra-
dycardia, which appeared to be anesthesia-related, making it difficult to evaluate contributions of the vector.
Introduction
The liver has been widely used for the expression oftherapeutic transgenes, both because of the accessibility
of hepatocytes via the blood stream through a fenestrated
epithelium and because of its importance for many metabolic
functions and the production of plasma proteins. Adeno-
associated virus (AAV)-based vectors are promising tools for
liver-directed gene transfer, and a number of different sero-
types have been evaluated for their potential to efficiently
transduce hepatocytes. Most of these experiments have been
performed in mice, and indeed high and also stable levels of
transgene expression were achieved in these animals (Van-
dendriessche et al., 2007; Cunningham et al., 2009; Wang et al.,
2010b). However, the mouse appears not to be an optimal
animal model in that it does not reflect some of the challenges
likely to be encountered in clinical gene therapy trials. Mice
lack preexisting neutralizing antibodies (NAbs) against AAV
serotypes derived from monkeys or humans such as AAV8,
which may confound expression data in nonhuman primates
(NHPs) and other animal models. More importantly, gene
transfer experiments with AAV carried out in NHPs demon-
strated the potential development of T cell responses against
the transgene, which is not the case in studies performed in
mice. Using self-complementary AAV7 expressing green
fluorescent protein (GFP) from a CB (cytomegalovirus-
enhanced chicken b-actin) promoter, the T cell response against
the transgene eliminated GFP expression 5 weeks after vector
administration (Gao et al., 2009). Similar experiments in NHPs
with AAV serotypes expressing GFP from the liver-specific
TBG (thyroid hormone-binding globulin) promoter demon-
strated a lower likelihood of developing transgene-specific T
cells, and the presence of those T cells did not necessarily
eliminate GFP expression (Wang et al., 2010a). An additional
complication in humans could be the development of T cells
against the capsid as observed in a clinical trial with AAV2
expressing factor IX (Manno et al., 2006; Mingozzi et al., 2007).
Although NHPs are the preferable model organism to test
therapeutic gene transfer to allow comparisons with hu-
mans, there are a very limited number of NHP disease
1Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104.
2Present address: Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605.
3Pathology and Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104.
4Present address: Vaccine Research Institute, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
5Present address: Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104.
6Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104.
*P.B. and G.G. contributed equally to this work.
HUMAN GENE THERAPY 22:985–997 (August 2011)
ª Mary Ann Liebert, Inc.
DOI: 10.1089/hum.2010.194
985
models available. Canine models of several human genetic
diseases are available and provide unique opportunities for
evaluating in vivo gene therapy (High, 2005; Casal and Ha-
skins, 2006; Haskins, 2009).
We previously tested several AAV serotypes as clinical
candidates for liver-directed gene transfer in mice (AAV8,
AAV7, AAV2, AAV6.2, AAVrh.64R1, AAVhu.37, AAVrh.8,
AAVrh.32.33) and subsequently in NHPs (AAV8, AAV-
hu.37, AAVrh.8) (Wang et al., 2010a,b). These vectors belong
to a larger group of AAV serotypes that have been isolated
from human and NHP tissues (Gao et al., 2002, 2004; Van-
denberghe et al., 2009). In the monkey experiments, the
vectors were administered intravenously at a dose of 31012
genome copies (GC)/kg and expressed GFP from the liver-
specific TBG promoter. On the basis of these studies, AAV8
emerged as the best performing candidate for clinical gene
therapy trials.
In the present report, we evaluated six of these AAV se-
rotypes in dogs, including the three serotypes that had been
tested in monkeys, using the same promoter (TBG) and dose
(31012 GC/kg) as was done in NHPs. These serotypes were
selected as initial clinical candidates for further detailed
analysis because of their superior liver transduction effi-
ciency compared with other members in the same clade in
our pilot studies. More specifically, dogs at 1.5 months of age
were injected via the cephalic vein with AAV8, AAV2,
AAV6.2, AAVhu.37, AAVrh.64R1, and AAVrh.8 and GFP
expression in liver was examined after 7 days and, in the case
of AAV2 and AAV8, also after 4 weeks. Two additional
AAV2-injected animals were evaluated after 12 days. We
further examined liver toxicity by serum chemistry, devel-
opment of T cells against transgene and capsid, and distri-
bution of vector genomes in liver and spleen. In addition,
AAV8 was infused into two adult dogs via the hepatic artery
at higher doses (1.821013 and 7.91012 GC/kg) and vital
signs and other clinical data were recorded during and after
the administration. The livers of these two animals were
examined on days 7 and 35, respectively.
Materials and Methods
Vectors
AAV vectors (serotypes 8, 2, 6.2, hu.37, rh.64R1, and rh.8)
expressing enhanced GFP (EGFP) were produced and purified
by the Penn Vector Core at the University of Pennsylvania
(Philadelphia, PA) as described previously (Gao et al., 2006;
Wang et al., 2010a). All vectors contained the liver-specific TBG
promoter downstream of two copies of the a1-microglobulin/
bikunin enhancer sequence (Ill et al., 1997, Gao et al., 2006).
Animals
The outbred dogs used in this study were mixed breeds,
with most animals based on a German shepherd background
mixed with beagle, springer spaniel, corgi, plott hound,
Newfoundland, and Irish setter. They were maintained at the
School of Veterinary Medicine at the University of Pennsyl-
vania under National Institutes of Health and U.S. Depart-
ment of Agriculture guidelines for the care and use of
animals in research. The study was performed according to a
protocol approved by the Office of Environmental Health
and Radiation Safety, the Institutional Biosafety Committee,
and the Institutional Animal Care and Use Committee of the
University of Pennsylvania. For the experiments performed
in young dogs, animals were injected at 1.5 months of age via
the cephalic vein with vector (31012 GC/kg) diluted in 4ml
of phosphate-buffered saline (PBS). Dogs were sacrificed by
intravenous injection of sodium phenobarbital (80mg/kg) at
7, 12, or 28 days and the liver and spleen were removed.
The two adult dogs received vector (AAV8.TBG.EGFP) by
infusion into the hepatic artery with 1.821013 GC/kg in
8.6ml of PBS (S473) or 7.91012 GC/kg in 8.7ml of PBS
(S468). Before injection, the vector solution was mixed with
3ml of contrast agent (Omnipaque; GE Healthcare Life Sci-
ences, Piscataway, NJ) for fluoroscopy. In both animals,
propofol was intravenously administered to induce anesthe-
sia, which then was maintained with isoflurane. The right
femoral artery was exposed and a no. 5 French introducer
was advanced into the artery. An injection catheter was then
introduced into the hepatic artery under fluoroscopic guid-
ance for vector delivery. Propofol was administered intrave-
nously so that respiration could be temporarily suppressed
for better visualization of the catheterization procedure. Both
dogs received the nonsteroidal antiinflammatory drug car-
profen (2.2mg/kg) for 3 days after the procedure. More de-
tails of the anesthesia protocol and vector administration are
described in Results and summarized in Figs. 9 and 10.
Analysis of GFP expression
Liver samples were fixed overnight in formalin, washed in
PBS for 30min, and frozen in O.C.T. compound (Sakura Fi-
netek USA, Torrance, CA) for cryosectioning. For quantifica-
tion of GFP expression, 10 random images were taken from
sections of different lobes at identical microscope and camera
settings. GFP expression was quantified both for the percent-
age of area occupied by GFP-positive cells in liver sections as
well as for the intensity of GFP fluorescence in tissue sections
as described previously (Wang et al., 2010a). Briefly, the
percentage of GFP-positive liver area was obtained by
‘‘thresholding’’ the images, that is, selecting the area consid-
ered GFP-positive based on comparison with liver sections
from untreated dogs, and calculating the average percentage
of this area. GFP intensity was determined by calculating the
sum of the intensity values of all pixels of each image minus
the background values as measured from untreated control
livers. The average value from 10 images is shown for both
measurements in Fig. 2. Values of pwere calculated by Student
t test. ImageJ software (Rasband, 1997–2006; National In-
stitutes of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/)
was used for all of the described quantification procedures.
NAb assays
NAb assays were performed as described (Calcedo et al.,
2009) by incubating the corresponding serotype of AAV.CMV.
LacZ with 2-fold dilutions of heat-inactivated dog serum and
determining b-galactosidase expression in Huh7 cells. The
highest serum dilution inhibiting LacZ expression by at least
50% corresponds to the reported NAb titer.
Vector biodistribution and RNA analysis
DNA was extracted from tissues, using a QIAamp DNA
mini kit (Qiagen, Valencia, CA). For liver, samples were
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taken from different lobes of each animal. Detection and
quantification of vector genomes in extracted DNA were
performed by real-time PCR as described previously (Bell
et al., 2005). Vector genome copies were calculated per diploid
genome, assuming a DNA content of 6.6 pg per cell nucleus.
GFP RNA in liver and spleen was quantified by real-time
reverse transcriptase-PCR as described (Livak and Schmitt-
gen, 2001; Gao et al., 2009), using glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) RNA as reference.
Lymphocyte isolation and interferon-g
enzyme-linked immunospot assay
Peripheral blood mononuclear cells (PBMCs) were
isolated from whole blood collected in EDTA-containing
Vacutainer tubes after Ficoll density-gradient centrifugation.
At the time of necropsy, lymphocytes were also isolated from
liver by Percoll density-gradient centrifugation and from
spleen by grinding through 40-mm (pore size) strainers (BD
Biosciences, San Jose, CA). Enzyme-linked immunospot
(ELISpot) assays to detect canine interferon (IFN)-g were
performed with the canine IFN-g ELISpot development
module and ELISpot blue color module (R&D Systems,
Minneapolis, MN), in accordance with the manufacturer’s
instructions. T cells were stimulated with a GFP peptide li-
brary or peptide pools for AAV2 and AAV8 viral protein-1
(VP1) as described (Wang et al., 2007).
Results
Liver-directed gene transfer with AAV serotypes
in young dogs (1.5 months)
Levels of GFP expression. Transgene expression from
six AAV serotypes was evaluated in liver of 1.5-month-old
dogs 7 days after vector administration. Dogs received, via
the cephalic vein, AAV serotype 2, 8, 6.2, hu.37, rh.64R1, or
rh.8 (n¼ 3–5 dogs per serotype) expressing GFP from the
liver-specific TBG promoter. Seven days later we examined
the livers and quantified sections both for GFP intensity and
the percentage of GFP-positive liver area (Figs. 1 and 2). Both
measurements were correlated: in general, the more trans-
duced hepatocytes that were present, the higher the value for
overall GFP intensity. This implied that there was no ab-
normal transduction pattern among the tested serotypes, that
is, there were no liver sections with either many weakly
transduced hepatocytes, or few strongly transduced hepa-
tocytes (Fig. 1). GFP expression was restricted to hepato-
cytes; no other cell types in the liver such as Kupffer cells or
endothelial cells were found to be GFP-positive. We further
examined the spleens of all dogs that were found to be
negative for GFP fluorescence (data not shown).
AAV8 showed the highest levels of GFP expression, fol-
lowed by AAVrh.64R1 and AAVrh.8 (Figs. 1 and 2). How-
ever, GFP expression was relatively low, especially when
compared with previous data on NHP livers from animals
that had received the same dose of vector (Wang et al., 2010a),
and evenmore so inmice that had received a comparable dose
of 11011 GC per animal (Wang et al., 2010b). However, in the
mouse study, a CB promoter was used instead of the TBG
promoter. In the dogs, the average transduced liver area for
AAV8 was 2.86 1.3%. The average transduced areas for
AAVrh.64R1 and AAVrh.8 were 2.35 0.8 and 1.39 1.2%,
respectively. Even lower GFP expression levelswere observed
for AAVhu.37 (0.25 0.02%) and AAV6.2 (0.10 0.05%), well
below 1% of GFP-positive liver area (Figs. 1 and 2). AAV2 also
failed to produce any appreciable GFP expression in the livers
except for a few transduced hepatocytes that were occasion-
ally found. Compared with AAV8, these vectors achieved
82.2% (AAVrh.64R1), 48.6% (AAVrh.8), 8.7% (AAVhu.37),
FIG. 1. Green fluorescent protein
(GFP) expression in dog liver 7 or 28
days after gene transfer via the ce-
phalic vein with the indicated AAV
serotype at a dose of 31012 genome
copies (GC)/kg. Four animals per
group were analyzed except for the
day 28 time point, which included
only two dogs per group. For the
day 7 animals, only the two livers
with the strongest GFP expression
are shown. Bottom: Liver images at
higher magnification, demonstrat-
ing hepatocyte transduction. Scale
bars: 100mm (low magnification)
and 50mm (high magnification).
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3.5% (AAV6.2), and 2.8% (AAV2) of the AAV8 area trans-
duction value. The GFP intensity values showed a higher
degree of variability than the area values within the AAV8
group on day 7. Values of p were determined between the
AAV8 group and each of the other groups examined on day 7.
There was no statistically significant difference ( p 0.05) be-
tween the GFP intensity of the AAV8 group compared with
AAVhu.37 ( p¼ 0.068), AAVrh.8 ( p¼ 0.214), AAVrh.64R1
( p¼ 0.423), AAV6.2 ( p¼ 0.058), and AAV2 ( p¼ 0.097).
However, the percentages of transduced liver area were sig-
nificantly different from AAV8 with AAVhu.37 ( p¼ 0.007),
AAV6.2 ( p¼ 0.005), and AAV2 ( p¼ 0.014) but not with
AAVrh.8 ( p¼ 0.136) and AAVrh.64R1 ( p¼ 0.586).
The livers of two additional animals that received AAV2
were analyzed after 12 days, the rationale being that AAV2
may need a longer time to express the transgene. After 12 days
GFP expression was not detected except for a few individual
GFP-positive hepatocytes that could occasionally be found
(Fig. 2).
We further analyzed liver and spleen from selected ani-
mals for the presence of GFP transcripts, to see whether GFP
RNA is present in organs that did not show GFP fluorescence
(Table 1). As observed previously in our NHP study (Wang
et al., 2010a), low levels of GFP RNA (relative to control
spleen from an untreated dog) are detectable in spleen from
all animals tested despite the presence of relatively high copy
numbers of vector genomes in some of the spleens (compare
with Fig. 3). For example, animal M2395 had about the same
amount of vector genome copies in liver as in spleen, but the
GFP RNA level was more than 400-fold higher in liver than
in spleen. The overall low levels of GFP RNA indicate that
the TBG promoter was not active in this organ and is indeed
liver-specific. Also, those livers where no GFP had been de-
tected by microscopy showed similar low values for GFP
transcripts, in contrast to liver from dogs treated with AAV8
and analyzed after 7 days (Table 1). The GFP fluorescence
data therefore correlate well with the GFP RNA values.
Prevalence and impact of neutralizing antibodies. The
presence of preexisting antibodies is an important factor for
gene therapy and impacts strongly on transgene expression.
Therefore, the animals were prescreened for the presence of
NAbs against the administered serotypes (see bottom leg-
ends in Figs. 2 and 3). No NAbs were detected against
AAVrh.64R1 and AAVrh.8 in the animals treated with these
serotypes, which all showed corresponding titers below 1:5.
A screen of 21 animals from the dog colony for AAV2 and
AAV8 revealed only one animal with a titer of 1:5 for AAV2;
all other dogs had titers below 1:5 for both serotypes (the
baseline samples from the AAV2 and AAV8 animals were
not available). However, we found preexisting NAbs against
AAV6.2 and AAVhu.37 in our dogs. The dogs that received
AAV6.2 and AAVhu.37 (four animals each) had titers of
preexisting NAbs against the corresponding serotype of
1:40–1:80 and 1:10, respectively (Figs. 2 and 3). Thus, the
lower levels of GFP expression in dogs with AAV8,
FIG. 2. GFP intensity (top) and percentage of GFP-positive area (bottom) of liver sections as a quantitative measure of
transgene expression. GFP intensity was calculated as the sum of brightness values of each image minus the background
value. For both measurements, 10 random images of sections from different parts of the liver were taken for each animal and
the mean SD is shown. The average values for each group are indicated above the columns. Neutralizing antibody (NAb)
titers (shown as reciprocal of serum dilution) are for the corresponding vector at the time before injection for each animal. For
AAV2 and AAV8, the individual titers are not known, but testing of 21 dogs from the same colony revealed titers below 1:5
and in one case equaling 1:5.
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AAVrh.64R1, and AAVrh.8, compared with NHPs and mice,
could not be explained by the presence of NAbs. Likewise,
the almost complete absence of transgene expression from
AAV2 appeared not to be related to the presence of inter-
fering antibodies. The failure of transgene expression from
AAV2 was not too surprising in the context of the relatively
low performance of AAV8 in dogs, as AAV2 is known to
have lower transduction levels in monkey and mouse liver
compared with AAV8 (Lebherz et al., 2004; Sarkar et al., 2004;
Thomas et al., 2004; Davidoff et al., 2005).
Vector genomes in liver and spleen. As expected, the
number of genome copies for AAV6.2 administered in the
presence of preexisting NAb titers equal to 1:40–1:80 aver-
aged only 0.43 0.2 GC per diploid genome, corresponding
to the low GFP expression. AAV2 also had a low range of
vector genomes in the liver, with an average of 1.02 0.4 GC
per diploid genome on day 7. The genomes of all other se-
rotypes, however, could be found in a range of about 5–10
GC per diploid genome (Fig. 3). Dog M2450 was an excep-
tion with 28.7 GC per genome but only modest GFP ex-
pression (1.8% liver area). Animals treated with AAVhu.37
showed a discrepancy between vector genomes in the liver
and GFP expression. The low levels of GFP expression in this
group correlated with the presence of preexisting NAbs for
AAVhu.37 (titer, 10), but were in contrast to relatively high
numbers of vector genomes (average, 7.46 1.9 GC per
diploid genome). Whether this discrepancy was related to
NAb is impossible to sort out because we did not evaluate
this vector in animals that were NAb negative.
In previous studies with NHPs, those animals with pre-
existingNAbs against theAAV serotype administered (AAV8,
AAVhu.37, AAVrh.8) tended to have an increased number of
vector genome copies in spleen, with a spleen-to-liver ratio
greater than 1 (Wang et al., 2010a). This was examined in the
dogs. Asmentioned, the highest preexistingNAbs observed in
the dogs were those against AAV6.2. These animals had only
low copy numbers of AAV genomes in the liver, but did not
show higher levels in the spleen. Only in the AAV2-treated
animals and in one of the long-termAAV8 dogs did the spleen
containmore vector genomes than the liver, but these dogs did
not have preexisting NAbs against these vectors (Fig. 3). The
phenomenon of redirection of AAV into the spleen in the
presence of NAbs may, therefore, be specific for NHPs, al-
though more canine studies need to be performed.
Liver enzyme levels. Serum liver enzyme activity in all
the animals that had received the various AAV serotypes was
measured on day 7 and also on day 12 for the additional dogs
Table 1. Levels of Green Fluorescent Protein (GFP)
Transcripts in Liver and Spleen in the Absence
of Detectable GFP Fluorescence
Group Animal ID Relative GFP RNA levels
Liver
AAV2, day 7 M2402 4.53101
M2406 1.60101
AAV2, day 12 M2412 2.83101
M2414 1.58101
AAV8, 4 weeks I268 1.55102
I269 7.60101
AAV8, day 7 M2396 5.85104
M2395 3.00104
untreated control I276 1100
Spleen
AAV2, day 7 M2402 6.72100
M2406 1.28101
AAV8, day 7 M2396 1.05102
M2395 7.14101
AAVrh.64R1, day 7 M2440 1.16102
M2452 1.03102






untreated control I276 1100
Shown are relative copy numbers of GFP RNA per 50ng of total
RNA normalized for GAPDH RNA levels and values from corre-
sponding control tissues from an untreated dog (values from control
liver and spleen¼ 1). Liver GFP RNA values are shown for livers
with no visible GFP fluorescence (AAV8 at 4 weeks and AAV2 on
days 7 and 12) compared with livers with the highest GFP expression
(AAV8 on day 7). Relative copy numbers of spleen GFP RNA are
shown for the two dogs from each group with the strongest liver
GFP fluorescence on day 7. This also includes the spleen with the
highest copy number of vector DNA for each group. No GFP
fluorescence was detectable in the spleens of any of the animals.
FIG. 3. Vector genome
copies per diploid genome in
liver and spleen on the indi-
cated days after gene trans-
fer. NAb titers (shown as the
reciprocal of serum dilution)
are for time before injection
as in Fig. 2.
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treated with AAV2. We did not observe elevations in aspar-
tate aminotransferase (AST) or alanine aminotransferase
(ALT) above the normal upper limit except for animal M2442
(AAVrh.8), which showed a mild increase in AST (75U/liter;
the normal upper limit is about 65U/liter). Two samples
(M2448, M2409) could not be evaluated because of hemolysis.
Absence of long-term transgene expression and cytotoxic
T lymphocyte responses. The stability of GFP expression
for AAV2 and AAV8 was evaluated. Two dogs each received
AAV2 or AAV8 and the liver was examined for GFP ex-
pression after 4 weeks. AAV2 did not produce any GFP-
positive cells in the liver, as expected, because this vector
failed to express at earlier time points. However, GFP ex-
pression was also not present with AAV8 at 4 weeks (Fig. 1).
The same observation was made in an adult animal injected
with AAV8 as described in more detail below (Fig. 6). Al-
though we had not taken a biopsy and, therefore, cannot
determine with certainty whether AAV8 generated any
transient GFP expression, it appears that in all of the AAV8-
treated dogs GFP expression occurred and then was elimi-
nated through a T cell response against the transgene. IFN-g
FIG. 4. Time course of T
cell responses to GFP and
capsid in peripheral blood
mononuclear cells (PBMCs)
and lymphocytes isolated
from spleen and liver, de-
termined by IFN-g ELISpot
assay. T cells were stimu-
lated with GFP or peptide
pools (A, B, C) correspond-
ing to AAV2 and AAV8
capsid, respectively, and the
number of IFN-g-secreting
cells in response to antigen
stimulation was determined.
T cell responses to GFP can
be observed in the two ani-
mals that received AAV8 on
day 27. SFC, spot-forming
cells.
FIG. 5. Top: Liver enzyme values (left, ALT; right, AST) before injection and at 1-week intervals in the animals from the long-
term study.No enzyme levels elevated above the normal upper limitswere observed although therewas a slight increase inAST
on day 14 in all dogs and also a transient moderate elevation of ALT in one of the dogs (I268) on day 21. Arrows indicate upper
normal levels for ALT and AST. Bottom: Hematoxylin and eosin (H&E)-stained liver sections on day 27, showing infiltrates in
the AAV8-treated animals but not the AAV2-treated animals. Scale bar: 50 mm.
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ELISpot assays from splenocytes showed the presence of
GFP-specific T cells in spleen on day 27 after injection of
AAV8, but not after injection of AAV2 (Fig. 4). There was
also a weaker T cell response against GFP among peripheral
blood mononuclear cells (PBMCs) on days 14 and 27 after
AAV8 vector treatment and a borderline response on day 27
in lymphocytes from liver (an ELISpot count was considered
positive if more than three times the number of spots was
observed as in the control without peptide and having a
minimum of 55 spots). There was no T cell response against
the capsid of either AAV8 or AAV2 at any time point (Fig. 4).
Consistent with the ELISpot data, lymphocytes infiltrating
the liver were visible on day 27 in hematoxylin and eosin
(H&E)-stained sections from the AAV8-treated dogs but were
more or less absent in the AAV2-treated animals (Fig. 5).
These infiltrates typically surrounded the central veins and
portal areas; however, more severe indicators of liver in-
flammation such as mitotic or apoptotic hepatocytes were not
found.
There was a 4- to 5-fold reduction in AAV8 genome copy
numbers in liver on day 28 (average, 2.16 0.06 GC per
diploid genome) compared with copy numbers in the dogs
examined on day 7 (average, 9.74 1.62 GC per diploid ge-
nome), suggesting again that after initial gene transfer a
cellular immune response eliminated some of the GFP-ex-
pressing hepatocytes. An alternative explanation for some of
the reduction in vector genomes was further growth of the
liver in these animals. Interestingly, despite the development
of GFP-specific T cells and infiltrating lymphocytes in the
AAV8-injected dogs, there was only a moderate elevation in
the activity of liver enzymes AST and ALT, but still below
the upper normal limit (Fig. 5).
Liver-directed gene transfer
with AAV serotypes in adult dogs
Having established AAV8 as the best performing serotype
in young dogs, we wanted to evaluate the toxicity of this
serotype at higher doses in adult animals and look at po-
tential acute toxicity when delivering AAV8 directly into the
hepatic artery by a surgical procedure. An important aspect
of acute toxicity is hemodynamic instability at the time of or
immediately after gene transfer. No overt manifestations of
hypotension have been described after AAV gene transfer in
preclinical and clinical trials; however, subclinical evidence
of hypotension due to vasodilation or bradycardia has not
been systematically evaluated through careful hemodynamic
monitoring. To this end, two adult dogs weighing 18 kg
(S473) and 20 kg (S468) were infused with AAV8.TBG.EGFP
through the hepatic artery. S473 received a dose of 1.821013
GC/kg and the liver was analyzed 1 week after vector ad-
ministration. S468 received 7.91012 GC/kg of the same
vector and was sacrificed 5 weeks later.
Level and stability of GFP expression. GFP expression in
liver 1 week after injection of S473 (Fig. 6) was clearly
stronger, with 17.0 11.8% of the liver area positive com-
pared with an average of 2.86 1.3% in the younger animals
that received a lower dose. There was no visible GFP ex-
pression in liver from S468 examined at the time of sacrifice 5
weeks after injection. Infiltrates in the liver of S468 were not
present in the dog that was examined after only 1 week (Fig.
6), consistent with the hypothesis that transient GFP ex-
pression was silenced by a T cell response. A further indi-
cator of a T cell response against the transgene in S468 was a
transient elevation in liver enzyme activity, with ALT
reaching a maximum of 1488U/liter (normal upper limit is
about 90U/liter) and AST peaking at 370U/liter (normal
upper limit is about 65U/liter) (Fig. 7). The increase in liver
enzymes was accompanied by weight loss from 20 kg to less
than 18 kg on day 27. This weight loss was temporary and
the dog regained weight by 1 month after vector adminis-
tration (Fig. 7).
An ELISpot analysis showed the development of GFP-
specific T cells on day 20 in PBMCs (1045 spots per 106 cells),
although this result did not meet the criterion of being 3-fold
over the background value to be considered truly positive
(the unstimulated control on day 20 showed 490 spots per
106 cells). However, this criterion was met with T cells iso-
lated from liver on day 35 after injection (325 spots per 106
cells; unstimulated control, 105 spots per 106 cells), demon-
strating the presence of GFP-specific T cells in this organ. A
borderline value was also observed in splenocytes at this
time point (235 spots per 106 cells, unstimulated control, 80
spots per 106 cells). Frequencies of T cells directed against the
AAV8 capsid from PBMCs, spleen, and liver were not found
FIG. 6. GFP expression and
histopathology in liver after
administration of AAV8.TBG
.EGFP to large dogs. (a and
b) Animal S473 (16.7 kg;
dose, 1.821013 GC/kg): GFP
expression 1 week after vec-
tor administration as shown
in two different lobes. (d and
e) Animal S468 (20 kg; dose,
7.91012 GC/kg): liver 5
weeks after vector adminis-
tration; no GFP expression is
visible. (c and f) H&E-stained
liver sections show large in-
filtration sites in S468 (f),
which are absent in S473 (c).
Scale bars: (a, b, d, and e)
100 mm; (c and f) 50 mm.
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to exceed the background counts and were, therefore, not
considered positive (Fig. 8).
Vector genome copies were further analyzed in liver and
were low at 5 weeks (2.1 0.5 GC per diploid genome)
compared with liver examined 1 week after vector admin-
istration (59.2 7.0 GC per diploid genome), indicating the
elimination of transduced hepatocytes by a cytotoxic T cell
response. Direct comparison between these two animals is
complicated because they were given slightly different doses.
Changes in vital signs during vector infusion. In contrast
to the young animals, the two adult dogs received the vector
by infusion into the hepatic artery, an invasive procedure
requiring anesthesia. A key aspect of these studies was an
assessment of cardiopulmonary toxicity as measured by
changes in vital signs (e.g., heart rate, blood pressure, re-
spiratory rate, and O2 saturation). Although this kind of
toxicity has not been associated with systemic delivery of
AAV, it was the dose-limiting toxicity associated with in-
travascular administration of adenoviral vectors in subjects
with cancer (Reid et al., 2002).
A drop in blood pressure and heart rate was seen during
this procedure. To determine whether the vector had played
a role in lowering these two parameters we compared the
kinetics of vital signs with the time points of vector infusion
and administration of anesthetics (shown in Fig. 9 for S473
and Fig. 10 for S468).
In animal S473, body temperature and oxygen saturation
(SpO2) showed some fluctuations, with the lowest body
temperature at 38.78C (98.18F) and the lowest SpO2 at 92%.
The dog was mechanically ventilated at times as indicated in
Fig. 9 (circles, bottom panel). Systolic blood pressure (mea-
sured by Doppler ultrasound) and heart rate dropped during
anesthesia. The decrease in both measures started about
50min before the vector was given. Both values then fell
continuously from 155 mmHg and 165 bpm and reached
their lowest levels, 60 mmHg and 95 bpm, respectively,
during and after the vector infusion (Fig. 9).
Dog S468 received 11ml of saline before the vector solu-
tion was infused. As in the first dog, temperature and SpO2
showed fluctuations with minima at 35.78C (96.48F) and 98%,
respectively. The heart rate started to fall from 152 bpm
shortly after induction of anesthesia and about 1 hour before
saline administration, and subsequently the vector was given
(Fig. 10). The lowest heart rate (88 bpm) was reached during
vector administration at 10:05 a.m. Systolic, mean, and dia-
stolic blood pressure were monitored with an arterial line.
After the start of anesthesia, the blood pressure began to fall
FIG. 7. Changes in liver enzyme levels and weight in animal
S468 after vector administration. Normal upper values for
ALT, AST, and alkaline phosphatase (alk. phos.) in dogs are
about 90, 65, and 155U/liter, respectively.
FIG. 8. Development of T cells
against transgene and capsid in
animal S468 determined by IFN-
g ELISpot. Top: Time course of T
cell frequencies in PBMCs
against GFP and AAV8 capsid
(peptide pools 8A, 8B, 8C; con-
trol, C). Bottom: Frequencies of
GFP and capsid-specific T cells
isolated from spleen and liver
compared with PBMCs on day
35 after vector administration.
992 BELL ET AL.
and fluctuate. When saline was administered, the blood
pressure dropped within 5min (systolic from 98 to 89
mmHg, mean from 77 to 59 mmHg, diastolic from 62 to 29
mmHg) but recovered within another 5min to the values at
the beginning of saline injection. Similarly, when the vector
was infused, blood pressure fell again within 5min (systolic
from 100 to 80 mmHg, mean from 78 to 53 mmHg, diastolic
from 60 to 42 mmHg) but also increased again within the
next 5–10min (Fig. 10).
As discussed below in more detail, the described kinetics
of heart rate and blood pressure suggest that the anesthesia
procedure rather than toxicity of the vector had caused these
complications.
Discussion
Gene transfer in young dogs
A large number of novel AAV serotypes has been
described (Gao et al., 2002, 2004; Vandenberghe et al., 2009), a
subset of which had been screened previously for their per-
formance for hepatic gene transfer in mice and NHPs (Wang
et al., 2010a,b). Because dogs are an important large animal
model for gene therapy studies, studies were extended by
testing a selection of the most promising AAV serotypes in
1.5-month-old dogs for transduction efficiency in liver,
stability of transgene expression, and immunogenicity.
Among the six serotypes evaluated (AAV8, AAV2, AAV6.2,
FIG. 9. Vital signs of dog S473
(18kg) around the time of vector
administration. Temp, temperature
(8F); SpO2, percent oxygen satura-
tion measured by pulse oximetry;
HR, heart rate (bpm); BP, systolic
blood pressure measured by
Doppler ultrasound (mmHg); RR,
respiratory rate (rpm). Circles in the
respiratory rate plot indicate me-
chanical ventilation. The time scale
on the x axis between 10:20 and
10:40 is doubled to accommodate
additional data points. Times of
propofol boluses, lidocaine admin-
istration, and vector infusion are
shown.
FIG. 10. Vital signs of dog S468
(20kg) around the time of vector
administration. Temp, temperature
(8F); SpO2, percent oxygen saturation
measured by pulse oximetry; HR,
heart rate (bpm); BP, blood pressure
(systolic, mean, and diastolic BP
measured with an arterial line,
mmHg); RR, respiratory rate (rpm).
Times of propofol boluses, saline,
and vector infusion are shown.
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AAVhu.37, AAVrh.64R1, AAVrh.8), AAV8 emerged again as
the best performing serotype leading to the highest levels of
transgene expression in liver as observed previously in mice
and NHPs.
GFP expression in the dogs was relatively low; we did not
reach the high levels of GFP expression (23.7 and 40.1% of
liver area) and correspondingly high numbers of vector ge-
nomes (17.4 and 28.9 GC per diploid genome) that we had
detected in the best performing NHPs that received AAV8
(Wang et al., 2010a). The highest GFP levels in dogs were
found with AAV8 but did not exceed 4.6% of GFP-positive
liver area and a maximum of 12 vector GC per diploid ge-
nome (Fig. 2). In the dogs, a similar correlation was seen
between genome copies in the liver and GFP expression
levels as was the case in NHPs, with the exception of one dog
(M2450) that had received AAVrh.64R1 and showed a high
number of vector genomes (28.75 GC per diploid genome)
but only low GFP expression (1.82% GFP-positive area).
Stable transgene expression was not achieved with AAV8
in the dogs. Four weeks after vector administration, no GFP
fluorescence was visible, and the presence of GFP-specific T
cells and infiltrates in the liver indicated that transient ex-
pression of GFP had occurred and then was eliminated by
the observed T cell response. The cytotoxic T lymphocyte
(CTL) response in our dogs against GFP expressed in liver is
therefore similar to T cell reactions in NHPs (and therefore
probably humans), contrary to what was observed in mice,
in which liver-directed gene transfer with AAV8 normally
fails to elicit T cell responses that eliminate transgene ex-
pression (reviewed by Mays and Wilson, 2011). However,
stable transgene expression in liver has been described in
dog models of genetic diseases after receiving AAV expres-
sing the therapeutic transgene (Wang et al., 2000, 2005; Beaty
et al., 2002; Jiang et al., 2006). In our study, the transgene was
GFP, a foreign protein known to be able to elicit potent im-
mune responses in NHPs, whereas therapeutic transgenes
that are almost identical to the endogenous protein typically
cause only mild if any T cell responses. However, two he-
mophilia B dogs with null mutations in the factor IX (FIX)
gene did show sustained hepatic FIX expression from AAV
(Mount et al., 2002; Niemeyer et al., 2009). Detection of GFP
by fluorescence microscopy in tissue sections is likely to be
less sensitive than detection of FIX by ELISA, and low levels
of GFP RNA were present in the livers of the long-term an-
imals, making it possible that there was residual expression
of GFP at levels too low to be observed by microscopic ex-
amination. In our previously published experiments with
NHPs, GFP expression was obtained in the liver up to day 35
but only when a liver-specific promoter was used. The de-
velopment of GFP-specific T cells in liver on day 35 did not
necessarily prevent the continued expression of GFP in ma-
caques (Wang et al., 2010a). Because only three dogs (two
young dogs, one adult dog) were evaluated for sustained
GFP expression, and given the variability of hepatic GFP
expression observed in NHPs, we may not have examined
enough animals to exclude the possibility of long-term ex-
pression of GFP in liver.
The animals were injected at an age of 1.5 months, when
growth is still occurring. Dilution of episomal vector ge-
nomes in the growing liver 4 weeks after vector treatment
should therefore also be considered a factor that could di-
minish transgene expression. Experiments in mice treated
with AAV8 at various ages and evaluated at later time points
demonstrated a substantial loss of transgene expression in
those animals that were injected as newborns but increas-
ingly stable expression when injected at subsequent ages
(Cunningham et al., 2008, 2009). Our dogs were not injected
as newborns, making it unlikely that liver growth would
account for the complete loss of GFP expression. Complete
loss of expression was also observed in the adult animal after
5 weeks, further suggesting that liver expansion was not a
major factor leading to the absence of GFP at later time
points.
The number of AAV8 genomes in the liver of the younger
dogs on day 28 was reduced about 4- to 5-fold compared
with liver harvested on day 7 (Fig. 3), and was similarly low
in the adult animal 5 weeks after vector injection. In the adult
animal, this would suggest that a cellular immune response
eliminated some of the GFP-expressing hepatocytes. In the
younger animals, the drop in vector genome copies could
simply be due to dilution of episomal vector genomes in the
expanding liver, although a cellular immune response could
also play a role. Despite the absence of GFP expression at the
late time points, vector genomes were not completely elim-
inated (average, 2.16 0.06 GC per diploid genome). The
persistence of AAV genomes in liver, although potentially at
reduced numbers, after elimination of transgene expression
through a cytotoxic T cell response has been described pre-
viously, but the exact mechanism of this phenomenon re-
mains unknown (Gao et al., 2009; Somanathan et al., 2010;
Wang et al., 2010a).
AAV2 failed to produce visible GFP signals in liver on
days 7, 12, or 28 except for a few weakly fluorescent cells that
could occasionally be found (Fig. 2). In the long-term ani-
mals, no T cell elevations against GFP were observed, sug-
gesting that no transient expression of GFP had occurred.
The dogs that were sacrificed on day 12 after vector ad-
ministration did not show any elevation in liver enzymes,
again suggesting the absence of GFP expression. Together
these data suggest that AAV2 failed to express GFP. This is
in contrast to studies in which AAV2 was used successfully
in hemophilia dogs for hepatic expression of FVIII or FIX
(Wang et al., 2000; Harding et al., 2004; Jiang et al., 2006;
Niemeyer et al., 2009). We cannot rule out low levels of GFP
expression from AAV2 in liver that went undetected by
fluorescence microscopy, and in fact we observed a few
transduced hepatocytes in some of the animals along with
low levels of GFP RNA. A low number of transduced he-
patocytes similar to what we saw in our AAV2-treated dogs
could be sufficient to generate the observed levels of secreted
proteins in the hemophilia studies.
Gene transfer in adult dogs
In the two adult dogs that received AAV8, we observed
several complications during anesthesia. In contrast to our
experiments in the young dogs, these animals received
higher vector doses (1.821013 GC/kg in S473 and 7.91012
GC/kg in S468 vs. 31012 GC/kg in the young dogs), and
the vector was infused into the hepatic artery by a surgical
procedure instead of by intravenous injection. The higher
dose may have contributed to the liver toxicity made evident
by elevation of liver enzyme activity in animal S468, whereas
the young animals showed no rise in enzyme levels. Im-
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portantly, in both adult animals heart rate and blood pres-
sure dropped, raising a question concerning whether the
administration of the vector played any role in this phe-
nomenon.
In dog S473, both heart rate and blood pressure started to
decrease well before the vector infusion, suggesting no direct
involvement of the vector. There was a somewhat steeper
decline both in blood pressure and heart rate when the
vector was injected (between 10:15 a.m. and 10:20 a.m.), but
similar episodes of steep decreases could also be observed
before vector infusion for blood pressure (between 9:30a.m.
and 9:35 a.m.) and, although less pronounced, for heart rate
(between 9:45 a.m. and 9:50 a.m.). In animal S468, the heart
rate also started to fall and the blood pressure showed wide
fluctuations before the vector was given. An immediate drop
in blood pressure was observed when saline was injected
first and then a similar drop occurred when the vector was
infused, suggesting that the infusion of liquid rather than the
vector caused this phenomenon. Although the heart rate had
started to decrease with induction of anesthesia, there was a
steeper drop when the vector was administered (between
10:00 a.m. and 10:05 a.m.) that was not observed during the
preceding saline injection. However, a similar steep decrease
was seen at the beginning of anesthesia when 160mg of
propofol had been given, and it seems possible that the two
final propofol boluses (between 10:00 a.m. and 10:05 a.m.,
55mg total) out of a series of five boluses (between 9:45 a.m.
and 10:05 a.m., 130mg total) caused this drop.
A decrease in average values for blood pressure (systolic,
diastolic, and mean) and heart rate in dogs during anesthesia
has been described in a large-scale meta-analysis (Redondo
et al., 2007). In this study, propofol was used for induction in
1040 out of a total of 1281 studied cases. The animals in our
study received high doses of propofol during the procedure
(total, 11.4mg/kg for S473 and 14.5mg/kg for S468). Pro-
pofol is well known for its ability to cause a decrease in blood
pressure in humans (Grounds et al., 1985; Larijani et al., 1989;
Muzi et al., 1992; Robinson et al., 1994, 1997) as well as in
dogs (Musk et al., 2005). In the latter study, four groups of 20
dogs each received propofol to establish blood propofol
concentrations of 2.5, 3.0, 3.5, and 4.0 mg/ml. These concen-
trations induced anesthesia in 65, 80, 100, and 100% of the
dogs from each group, respectively. Occurrences of hypo-
tension, defined as a mean arterial blood pressure under 60
mmHg, were observed within several minutes in dogs from
all four groups (1 animal of 20 at 2.5 mg/ml propofol, 6 of 20
at 3.0 mg/ml, 3 of 20 at 3.5 mg/ml, 8 of 20 at 4.0 mg/ml) (Musk
et al., 2005). For comparison, in S468 a mean arterial blood
pressure of 60 mmHg or lower was reached at four time
points, with 53 mmHg as the lowest value (we did not
measure mean blood pressure in S473). In addition, iso-
flurane has also been described to induce lowering of blood
pressure in dogs (Hellebrekers, 1986; Cutfield et al., 1988;
Merin et al., 1991).
The extent to which intraarterial vector administration
yields higher transduction levels in liver, compared with
injection into a peripheral vein, cannot be established from
our study because of differences in dose and age of the an-
imals. Using AAV2 in mice, peripheral intravenous injection
has been reported to be less efficient in hepatocyte trans-
duction than intraarterial or intraportal administration
(Mingozzi et al., 2002; Grimm et al., 2003; Ohashi et al., 2005;
Berraondo et al., 2006). This was different with AAV8 tested
in NHPs, in which intraportal delivery gave comparable
transduction levels in liver as injection into a peripheral vein
(Nathwani et al., 2007).
Administration of AAV via hepatic artery has been per-
formed seemingly without adverse events in dogs as well as
in clinical trials in humans (Arruda et al., 2001; Manno et al.,
2006; Hasbrouck and High, 2008). Likewise, no complica-
tions were reported in dogs during AAV delivery through
the portal vein (Wang et al., 2005; Jiang et al., 2006; Sarkar
et al., 2006; Margaritis et al., 2009). The finding that a decrease
in blood pressure and heart rate was observed in both adult
dogs before the time of vector administration, the fact that
both parameters usually drop during anesthesia and espe-
cially after propofol administration, and the safety record of
AAV administration by surgical procedure suggest that the
AAV8 vector did not cause the observed changes in blood
pressure and heart rate. However, we cannot rule out an
independent contribution of the vector to hypotension/bra-
dycardia masked by the anesthesia effect. This study points
to the complexities in assessing key aspects of acute toxicities
in animal models and the need for careful evaluation, using
methods that will be deployed in clinical studies.
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